Results 1 to 10 of about 2,019 (87)
Varenicline for Smoking Cessation [PDF]
BMJ, 2007 What can we learn from the story so far? The public health burden of smoking is so enormous it is not surprising that varenicline—the most recently approved drug for smoking cessation—has been prescribed so widely and discussed extensively. A linked paper by Svanstrom and colleagues (doi:10.1136/bmj.e7176) further explores the association between use
Jon O. Ebbert, Eric G. Tangalos
+16 more sources
Varenicline: quantifying the risk [PDF]
Canadian Medical Association Journal, 2011 We agree that there is a lack of clarity in Singh and colleagues’ article; it is very difficult for readers to follow how the various assumptions and extrapolations have been made.[1][1] The rather alarming figure of a 72% increase in serious cardiovascular events has been picked up by the ...
Brian S. Alper
+18 more sources
Varenicline for Tobacco Dependence [PDF]
New England Journal of Medicine, 2008 A 57-year-old man with a 60-pack-year history visits his primary care provider because he wants to quit smoking. He has a history of stable coronary artery disease, peripheral vascular disease, and hypertension. He also has severe obstructive lung disease (forced expiratory volume in 1 second, 39% of the predicted value) with a progressive increase in ...
J. Taylor Hays, Jon O. Ebbert
openalex +4 more sources
Varenicline: For smoking cessation
Kathmandu University Medical Journal, 1970 Varenicline, a partial agonist of α4β2 nicotinic acetylcholine receptor (nAChR), is the most recently approved drug for smoking cessation. Despite the availability of effective treatments for smoking cessation, such as nicotine replacement therapy and Bupropion sustained-release, abstinence rates remain less than optimal.
Pinakini K. Shankar, J. Rao
openaire +4 more sources
Smoking cessation therapy with varenicline
International Journal of Chronic Obstructive Pulmonary Disease, 2008 Smoking cessation is the only available intervention proven to halt progression of chronic obstructive pulmonary disease (COPD). The authors discuss the current existing treatment modalities and the role of a newly approved agent, varenicline, in promotion of smoking cessation.
Ganesh Krishna +2 more
openaire +5 more sources
Estimating the impact of treatment compliance over time on smoking cessation using data from ecological momentary assessments (EMA) [PDF]
arXiv, 2020 The Wisconsin Smoker's Health Study (WSHS2) was a longitudinal trial conducted to compare the effectiveness of two commonly used smoking cessation treatments, varenicline and combination nicotine replacement therapy (cNRT) with the less intense standard of care, nicotine patch.
arxiv
Varenicline in smokers with diabetes: A pooled analysis of 15 randomized, placebo‐controlled studies of varenicline [PDF]
Journal of Diabetes Investigation, 2016 AbstractAims/IntroductionStopping smoking deserves high priority in preventing complications of diabetes; however, only sparse data are available regarding the efficacy of pharmacotherapy in smokers with diabetes. We assessed the efficacy and safety of varenicline in smokers with diabetes who participated in 15 double‐blind, randomized, placebo ...
David Lawrence, Serena Tonstad
openaire +3 more sources
Varenicline as a Cause of Suicidal Outcomes [PDF]
Nicotine & Tobacco Research, 2015 Postmarketing analyses and case reports have associated varenicline use with suicidal behaviors. This article reviews postmarketing analyses, case reports, clinical trials, uncontrolled observational studies, controlled observational studies, and studies in smokers with psychiatric problems that have tested this association.The author searched the ...
openaire +3 more sources
Varenicline overdose in a teenager [PDF]
Clinical Toxicology, 2009 Varenicline (Chantix®) is a selective partial agonist of α4β2 nicotinic acetylcholine receptor subtypes. It is approved in the United States to aid with smoking cessation.
Amy Joy Hedlund +3 more
openaire +2 more sources